(Q40552135)

21 September 2017

1 reference

title

Pharmacotherapy of cognitive impairment in Alzheimer's disease: a review (English)

1 reference

21 September 2017

0 references

0 references

cognitive dysfunction

1 reference

S V Patel

1

1 reference

21 September 2017

publication date

1 April 1995

1 reference

Journal of Geriatric Psychiatry and Neurology

21 September 2017

published in

1 reference

21 September 2017

volume

8

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

81-95

1 reference

Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Selective loss of central cholinergic neurons in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Acetylcholine and choline levels in post-mortem human brain tissue: preliminary observations in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Nicotinic acetylcholine binding sites in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Evidence for cholinergic neurites in senile plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

The cholinergic hypothesis of geriatric memory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

The cholinergic hypothesis--ten years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Alzheimer disease: lack of effect of lecithin treatment for 3 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Oral physostigmine and lecithin improve memory in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Effects of physostigmine and lecithin on memory in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Clinical Response to Choline plus Piracetam in Senile Dementia: Relation to Red-Cell Choline Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Acute effects of oral pyridostigmine on memory and cognitive function in SDAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Fee-for-service research on THA: an explanation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Tacrine in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Multiple-dose arecoline infusions in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Intravenous nicotine in Alzheimer's disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Induction of depression with oxotremorine in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Intracerebroventricular bethanechol chloride infusion in Alzheimer's disease. Results of a collaborative double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Intraventricular bethanechol infusion for Alzheimer's disease: results of double-blind and escalating-dose trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

4-Aminopyridine in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Biochemical Assessment of Serotonergic and Cholinergic Dysfunction and Cerebral Atrophy in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Somatostatin content and release measured in cerebral biopsies from demented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Reduced cholinesterase activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of the Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Location of neuronal tangles in somatostatin neurones in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Minireview. Thyrotropin releasing hormone and CNS cholinergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Neurohypophyseal principles and memory processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Neuropeptide effects on memory in aged monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Treatment of Alzheimer's disease with a synthetic ACTH 4-9 analog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

The effect of ACTH4-9 analog (Org2766) on some cerebrospinal fluid parameters in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Vasopressin in Alzheimer's disease: a study of postmortem brain concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Cerebrospinal fluid vasopressin, oxytocin, somatostatin, and beta-endorphin in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Desamino-D-arginine-vasopressin (DDAVP) in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Pharmacology of thyrotropin-releasing hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

TRH attenuates scopolamine-induced memory impairment in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Naloxone and Alzheimer's disease. Cognitive and behavioral effects of a range of doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Multicenter trial of naloxone in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Effect of naltrexone on senile dementia of the Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Promotion of neuritogenesis in mouse neuroblastoma cells by exogenous gangliosides. Relationship between the effect and the cell association of ganglioside GM1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

GM-1 treatment of Alzheimer's disease. A pilot study of safety and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

The nerve growth factor 35 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Localization of nerve growth factor receptors in cholinergic neurons of the human basal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Choline acetyltransferase activity in striatum of neonatal rats increased by nerve growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Nerve growth factor as a potential treatment in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

An overview of pharmacologic treatment of cognitive decline in the aged.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Ergoloid mesylates for senile dementias: unanswered questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Hydergine in senile mental impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Hydergine: A Review of 26 Clinical Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

An ergot alkaloid preparation (Hydergine) in the treatment of dementia: critical review of the clinical literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Lack of efficacy of hydergine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

The effect of chronic hydergine treatment on the plasticity of synaptic junctions in the dentate gyrus of aged rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Double-blind, placebo-controlled, clinical, psychometric and neurophysiological investigations with oxiracetam in the organic brain syndrome of late life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Vinpocetine enhances retrieval of a step-through passive avoidance response in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

The safety and lack of efficacy of vinpocetine in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer's type: possible role in cell loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

The amyloid proteins of Alzheimer's disease as potential targets for drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Aluminum and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Brain Aluminum Distribution in Alzheimer's Disease and Experimental Neurofibrillary Degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Intramuscular desferrioxamine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Chelation therapy. Unproved modality in the treatment of Alzheimer-type dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Calcium Dependence of Toxic Cell Death: A Final Common Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Serum calcium levels in Alzheimer's disease: A finding and an aetiological hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Imaging of calcium and aluminum in neurofibrillary tangle-bearing neurons in parkinsonism-dementia of Guam

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Decreased cerebral blood flow precedes multi-infarct dementia, but follows senile dementia of Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Perspectives on the etiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Anti-inflammatory drugs and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Lack of effect of tryptophan treatment in demented gerontopsychiatric patients. A double-blind, crossover-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Clonidine treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Bromocriptine in presenile dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Memantine in the treatment of senile dementia of the Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Evaluation of zimeldine in Alzheimer's disease. Cognitive and biochemical measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Cyclandelate in the Treatment of Senility: A Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Naftidrofuryl--a double blind cross-over study in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Effects of chronic papaverine administration on mild senile organic brain syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Senile-presenile dementia: follow-up data on an effective psychotherapy-anticoagulant regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

The treatment of chronic cerebrovascular insufficiency. A double-blind study with pentoxifylline (‘Trental’ 400)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Effects of Hyperbaric Oxygen on Behavioral and Physiological Measures in Elderly Demented Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Double blind evaluation of methylphenidate (ritalin) hydrochloride; its use in the management of institutionalized geriatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Treatment of senile dementia and cerebellar disorders with phthalazinol. Cyclic AMP-increasing agent, phthalazinol, in therapeutic trials in hitherto incurable morbid conditions (I)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Thiamine and Alzheimer's disease. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198879500800202

10.1177/089198879500800202

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference